Ristriani Tutik, Nominé Yves, Laurent Cécile, Weiss Etienne, Travé Gilles
Laboratoire d'Immunotechnologie, UMR CNRS 7100, Ecole Supérieure de Biotechnologie de Strasbourg, 67400 Illkirch, France.
Protein Expr Purif. 2002 Dec;26(3):357-67. doi: 10.1016/s1046-5928(02)00570-3.
Interpretation of protein mutagenesis experiments requires the ability to distinguish functionally relevant mutations from mutations affecting the structure. When a protein is expressed soluble in bacteria, properly folded mutants are expected to remain soluble whereas misfolded mutants should form insoluble aggregates. However, this rule may fail for proteins fused to highly soluble carrier proteins. In a previous study, we analysed the biophysical status of HPV oncoprotein E6 fused to the C-terminus of maltose-binding protein (MBP) and found that misfolded E6 moieties fused to MBP formed soluble aggregates of high molecular weight. By contrast, preparations of properly folded E6 fused to MBP were monodisperse. Here, we have used this finding to evaluate the quality of 19 MBP-fused E6 site-directed mutants by using a light scattering assay performed in a fluorimeter. This assay guided us to rule out structurally defective mutants and to obtain functionally relevant E6 mutants selectively altered for two molecular activities: degradation of tumour suppressor p53 and DNA recognition.
蛋白质诱变实验的解读需要具备区分功能相关突变和影响结构的突变的能力。当一种蛋白质在细菌中表达为可溶时,正确折叠的突变体预计仍可溶,而错误折叠的突变体则应形成不溶性聚集体。然而,对于与高度可溶的载体蛋白融合的蛋白质,这一规则可能不适用。在先前的一项研究中,我们分析了与麦芽糖结合蛋白(MBP)C末端融合的人乳头瘤病毒癌蛋白E6的生物物理状态,发现与MBP融合的错误折叠的E6部分形成了高分子量的可溶性聚集体。相比之下,与MBP融合的正确折叠的E6制剂是单分散的。在此,我们利用这一发现,通过在荧光计中进行的光散射测定来评估19个与MBP融合的E6定点突变体的质量。该测定引导我们排除结构有缺陷的突变体,并选择性地获得针对两种分子活性发生改变且功能相关的E6突变体:肿瘤抑制因子p53的降解和DNA识别。